How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Venetoclax with a hypomethylating agent for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about venetoclax

Marketing authorisation indication

2.1 Venetoclax (Venclyxto, AbbVie) in combination with a hypomethylating agent is indicated for 'the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The cost of venetoclax is £299.34 for 7 x 100 mg tablets (excluding VAT; BNF online accessed September 2021). The cost of azacitidine is £220 per 100 mg vial (excluding VAT; BNF online accessed September 2021). Costs may vary in different settings because of negotiated procurement discounts.

The company has a commercial arrangement. This makes venetoclax available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.